| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.